GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi India Ltd (BOM:500674) » Definitions » Debt-to-EBITDA

Sanofi India (BOM:500674) Debt-to-EBITDA : 0.02 (As of Dec. 2023)


View and export this data going back to 1991. Start your Free Trial

What is Sanofi India Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sanofi India's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹51 Mil. Sanofi India's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was ₹139 Mil. Sanofi India's annualized EBITDA for the quarter that ended in Dec. 2023 was ₹7,976 Mil. Sanofi India's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.02.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Sanofi India's Debt-to-EBITDA or its related term are showing as below:

BOM:500674' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.02   Med: 0.02   Max: 0.03
Current: 0.02

During the past 13 years, the highest Debt-to-EBITDA Ratio of Sanofi India was 0.03. The lowest was 0.02. And the median was 0.02.

BOM:500674's Debt-to-EBITDA is ranked better than
96.97% of 661 companies
in the Drug Manufacturers industry
Industry Median: 1.69 vs BOM:500674: 0.02

Sanofi India Debt-to-EBITDA Historical Data

The historical data trend for Sanofi India's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi India Debt-to-EBITDA Chart

Sanofi India Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.03 0.02 0.03 0.02

Sanofi India Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 - 0.03 - 0.02

Competitive Comparison of Sanofi India's Debt-to-EBITDA

For the Drug Manufacturers - General subindustry, Sanofi India's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sanofi India's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi India's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Sanofi India's Debt-to-EBITDA falls into.



Sanofi India Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Sanofi India's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(51 + 139) / 8868
=0.02

Sanofi India's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(51 + 139) / 7976
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Sanofi India  (BOM:500674) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Sanofi India Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Sanofi India's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Sanofi India (BOM:500674) Business Description

Traded in Other Exchanges
Address
Saki Vihar Road, Sanofi House, CTS Number 117-B, L&T Business Park, Powai, Mumbai, MH, IND, 400072
Sanofi India Ltd is a drug manufacturing company that focuses on a range of therapeutic areas, including Diabetes, Cardiology, Consumer Healthcare, Hospital, Central Nervous System, and Anti-Histamines. The company's diabetes presence includes oral anti-diabetic products and insulin. The consumer healthcare area also maintains a nutraceutical portfolio. The company's export markets include Germany, the U.K., Australia, and Russia. The company utilizes strategic partnerships as a component of its growth strategy.

Sanofi India (BOM:500674) Headlines

No Headlines